The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
 
Florence Joly
Consulting or Advisory Role - 3A Pharmaceuticals & Diagnostics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca; BMS; Eisai; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Maria Jesus Rubio
No Relationships to Disclose
 
Xavier Paoletti
Honoraria - MSD Oncology
Consulting or Advisory Role - Daiichii Sankyo; MSD Oncology
Speakers' Bureau - Ipsen
 
Alison J. Davis
No Relationships to Disclose
 
Emma Hudson
Honoraria - Clovis Oncology; GlaxoSmithKline
Consulting or Advisory Role - Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genmab; GlaxoSmithKline; ImmunoGen; MSD; PharmaMar; Seagen
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup
 
Germana Tognon
Consulting or Advisory Role - GlaxoSmithKline; MSD
 
Ursula Hasler-Strub
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
 
Chel Hun Choi
No Relationships to Disclose
 
Mehmet Ali Vardar
No Relationships to Disclose
 
Stephanie Lheureux
Honoraria - AstraZeneca; GlaxoSmithKline; Merck; Roche/Genentech; Shattuck Labs
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck; Novartis; Roche/Genentech; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Toon Van Gorp
Consulting or Advisory Role - AstraZeneca (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
David Shao Peng Tan
Stock and Other Ownership Interests - Asian Microbiome Library
Honoraria - AstraZeneca; Bayer; Eisai; Foundation Medicine; Merck; MSD; Roche; Turbine
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; GlaxoSmithKline; Merck; MSD; Roche
Speakers' Bureau - Roche
Research Funding - AstraZeneca; Bayer; Karyopharm Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Merck; Novartis; Roche
 
Fabian Trillsch
Honoraria - AstraZeneca; Clovis Oncology; Eisai; MSD Oncology; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; Eisai Germany; Immunogen; MSD Oncology; Roche; Tesaro/GSK
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Immunogen; Tesaro/GSK
 
Lauriane Eberst
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
 
Céline Lescure
Travel, Accommodations, Expenses - Viatris
 
Anne-Claire Hardy-Bessard
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; MSD; Novartis; Pfizer; Seagen
 
Marie Chaix
No Relationships to Disclose